Shuttle Pharmaceuticals Enters Material Definitive Agreement
Ticker: SHPH · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Jan 28, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Shuttle Pharma signed a big deal on Jan 23rd, details TBD.
AI Summary
On January 23, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement or any associated dollar amounts. The report was filed on January 28, 2025.
Why It Matters
This filing indicates a significant new development for Shuttle Pharmaceuticals, potentially impacting its future operations and strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- January 23, 2025 (date) — Date of earliest event reported
- January 28, 2025 (date) — Filing date
FAQ
What is the nature of the Material Definitive Agreement entered into by Shuttle Pharmaceuticals Holdings, Inc. on January 23, 2025?
The filing states that Shuttle Pharmaceuticals Holdings, Inc. entered into a Material Definitive Agreement on January 23, 2025, but does not provide specific details about the agreement itself.
Were there any financial terms or dollar amounts associated with this Material Definitive Agreement?
The provided filing excerpt does not mention any specific dollar amounts or financial terms related to the Material Definitive Agreement.
What is the primary business of Shuttle Pharmaceuticals Holdings, Inc.?
Shuttle Pharmaceuticals Holdings, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
In which state is Shuttle Pharmaceuticals Holdings, Inc. incorporated?
Shuttle Pharmaceuticals Holdings, Inc. is incorporated in Delaware.
What is the principal executive office address for Shuttle Pharmaceuticals Holdings, Inc.?
The principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
Filing Stats: 686 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2025-01-28 16:10:34
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 87KB
- ex10-1_001.jpg (GRAPHIC) — 12KB
- 0001493152-25-003985.txt ( ) — 328KB
- shph-20250123.xsd (EX-101.SCH) — 3KB
- shph-20250123_lab.xml (EX-101.LAB) — 33KB
- shph-20250123_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: January 28, 2025 By: /s/ Anatoly Dritschilo Name: Anatoly Dritschilo Title: Chief Executive Officer